In addition, the efficacy of chidamide seemed to be higher than that of pralatrexate which led to an ORR of 29% with a CR rate of 11% for relapsed or refractory PTCL (25), but it was lower than that of Brentuximab vedotin which led to an ORR of 86% with a CR rate of 57% for ALCL (26).Therefore, future studies focusing on the impact of HDAC inhibitors on the survival benefit of specific subtypes are needed. This evidence concerns the gene HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma.